 Home > Active Ingredient News > Immunology News > A&R: Birth Outcomes in Women Taking Hydroxychloroquine During Pregnancy: A Prospective Cohort Study

A&R: Birth Outcomes in Women Taking Hydroxychloroquine During Pregnancy: A Prospective Cohort Study

 Last Update: 2022-05-15
 Source: Internet
 Author: User

Tags

1 6 diaminohexane

1 3 cyclohexanedione

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

OBJECTIVE: Results from a previous small study showed a favorable safety profile for

Methods: The study cohort included pregnant women who were prospectively enrolled in the MotherToBaby/Termatology Informatics study of autoimmune disorders in pregnancy who were receiving HCQ .

Results: Between 2004 and 2018 , 837 pregnant women met the study inclusion criteria, including 279 women who received HCQ during pregnancy and 279 control women who did not receive HCQ .

In this study, there was no evidence of an increased risk of structural birth defects or other adverse outcomes in women treated with HCQ during pregnancy, with the exception of head circumference at birth .

Source: Chambers, CD, Johnson, DL, Xu, R.

Chambers, CD, Johnson, DL, Xu, R.
, Luo, Y.
, Felix, R.
, Fine, M.
, Lessard, C.
, Adam, MP, Braddock, SR, Robinson, LK, Burke, L.
, Jones, KL and (2022), Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study.
Arthritis Rheumatol, 74: 711-724.
https://doi.
org/10.
1002/art.
42015

Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top Quality 99.9% Ritlecitinib Tosylate Immunoregulation API & Inflammation Inhibitor

CAS No.: 2192215-81-7

Pharmacy Grade; Food Grade

$200-250/G FOB

β-Alanine107-95-9

CAS No.: 107-95-9

$1-1.1/KG FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.